Good thing is the this person is obviously on-board the strategy for resurrecting EPG. So we don't have to worry about him/her dumping their shares at a profit.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%